TrialLancet (London, England)2012

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.